Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine. Read More
COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the novel coronavirus. In a new article, Ivan Gandayuwana of Strategic Directions International examines the multiple impacts COVID-19 is having on pharma. Read More
Kedrion, Kamada partner to combat COVID-19
Biopharmaceutical firms Kedrion Biopharma and Kamada are collaborating on the creation and clinical distribution of a plasma-derived anti-SARS-CoV-2 treatment product. Read More
Bringing order to the viral multiverse
A new taxonomic classification system for viruses has been proposed by the International Committee on Taxonomy of Viruses, the group that oversees the official classification of viruses and naming of taxa. A consensus statement on the proposal appears in Nature Microbiology. Read More
Quotient, CytoAgents develop COVID-19 cytokine storm treatment
A new collaboration between Quotient Sciences and CytoAgents will accelerate the development of a lead COVID-19 drug candidate to human clinical trials, the companies announced. Read More
Pneumagen's glycan therapy may be effective against SARS-CoV-2
Scottish glycobiology firm Pneumagen said that its multivalent carbohydrate-binding modules have shown positive antiviral activity for preventing SARS-CoV-2 infection in three separate in vitro studies. Read More
What is the impact of aerosolized SARS-CoV-2 in hospitals?
A study evaluating viral RNA from two hospitals in Wuhan, China, during the COVID-19 outbreak reveals that although there are several hotspots for airborne viral RNA within hospitals, the implementation of careful sanitization, proper ventilation, and open spaces can reduce the risk of exposure to the airborne virus. The results were published online in an April 27 article in Nature. Read More
WHO cautions against coronavirus 'immunity passports'
The World Health Organization (WHO) has published a report expressing caution about the value of antibody tests for the novel coronavirus and saying that evidence for immunity after exposure is lacking. Read More
Recursion launches dataset for COVID-19 drug discovery
Digital biology company Recursion has released an open-source RxRx19 dataset, the first human cellular morphological dataset of SARS-CoV-2, it said. Read More
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter